Clearmind Medicine Inc. Increase Decrease In Cash And Cash Equivalents
Clearmind Medicine Inc. (CMND) reported Increase Decrease In Cash And Cash Equivalents of $5.33 million for the 3-month period ending 2026-01-31, per its 6-K filed 2026-03-12.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents · last filed 2026-03-12
- Clearmind Medicine Inc. increase decrease in cash and cash equivalents for the quarter ending 2023-01-31 was 4.32M CAD.
- Clearmind Medicine Inc. increase decrease in cash and cash equivalents for the quarter ending 2022-01-31 was -1.79M CAD.
CAD
| Period end | Increase Decrease In Cash And Cash Equivalents 3 month | Increase Decrease In Cash And Cash Equivalents 12 month |
|---|---|---|
| 2023-01-31 | 4.32M CAD 6-K · filed 2023-03-17 | |
| 2022-10-31 | -4.42M CAD 20-F · filed 2023-02-06 | |
| 2022-01-31 | -1.79M CAD 6-K · filed 2023-03-17 | |
| 2021-10-31 | 4.27M CAD 20-F · filed 2023-02-06 | |
| 2020-10-31 | 329.15K CAD 20-F · filed 2023-02-06 |
USD
| Period end | Increase Decrease In Cash And Cash Equivalents 3 month | Increase Decrease In Cash And Cash Equivalents 6 month | Increase Decrease In Cash And Cash Equivalents 9 month | Increase Decrease In Cash And Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-01-31 | $5.33M 6-K · filed 2026-03-12 | $5.76M derived: sum of 2 quarters · filed 2026-03-12 | $4.79M derived: sum of 3 quarters · filed 2026-03-12 | $3.48M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-10-31 | $427.72K derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | -$549.46K derived: sum of 2 quarters · filed 2026-01-20 | -$1.86M derived: sum of 3 quarters · filed 2026-01-20 | -$2.65M 20-F · filed 2026-01-20 |
| 2025-07-31 | -$977.18K derived: 6-K 9 month − 6-K 6 month · filed 2025-09-11 | -$2.29M derived: sum of 2 quarters · filed 2025-09-11 | -$3.08M 6-K · filed 2025-09-11 | -$4.18M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-04-30 | -$1.31M derived: 6-K 6 month − 6-K 3 month · filed 2025-06-12 | -$2.10M 6-K · filed 2025-06-12 | -$3.21M derived: sum of 3 quarters · filed 2026-03-12 | -$3.83M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-01-31 | -$792.62K 6-K · filed 2026-03-12 | -$1.90M derived: sum of 2 quarters · filed 2026-03-12 | -$2.52M derived: sum of 3 quarters · filed 2026-03-12 | -$3.50M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-10-31 | -$1.11M derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | -$1.73M derived: sum of 2 quarters · filed 2026-01-20 | -$2.71M derived: sum of 3 quarters · filed 2026-01-20 | $1.15M 20-F · filed 2026-01-20 |
| 2024-07-31 | -$626.28K derived: 6-K 9 month − 6-K 6 month · filed 2025-09-11 | -$1.61M derived: sum of 2 quarters · filed 2025-09-11 | $2.25M 6-K · filed 2025-09-11 | $3.83M derived: sum of 4 quarters · filed 2026-01-20 |
| 2024-04-30 | -$980.05K derived: 6-K 6 month − 6-K 3 month · filed 2025-06-12 | $2.88M 6-K · filed 2025-06-12 | $4.46M derived: sum of 3 quarters · filed 2026-01-20 | $3.06M derived: sum of 4 quarters · filed 2026-01-20 |
| 2024-01-31 | $3.86M 6-K · filed 2025-03-13 | $5.44M derived: sum of 2 quarters · filed 2026-01-20 | $4.04M derived: sum of 3 quarters · filed 2026-01-20 | $5.92M derived: sum of 4 quarters · filed 2026-01-20 |
| 2023-10-31 | $1.58M derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | $182.03K derived: sum of 2 quarters · filed 2026-01-20 | $2.06M derived: sum of 3 quarters · filed 2026-01-20 | $5.30M 20-F · filed 2026-01-20 |
| 2023-07-31 | -$1.40M derived: 6-K 9 month − 6-K 6 month · filed 2024-09-16 | $477.94K derived: sum of 2 quarters · filed 2024-09-16 | $3.72M 6-K · filed 2024-09-16 | |
| 2023-04-30 | $1.88M derived: 6-K 6 month − 6-K 3 month · filed 2024-06-13 | $5.12M 6-K · filed 2024-06-13 | ||
| 2023-01-31 | $3.24M 6-K · filed 2024-03-19 | |||
| 2022-10-31 | -$3.24M 20-F · filed 2025-01-22 | |||
| 2022-04-30 | -$2.63M 6-K · filed 2023-06-14 | |||
| 2021-10-31 | $3.13M 20-F/A · filed 2024-03-18 |